Related Experiment Videos
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide
M Romano1, A Mezzetti, C Marulli
1Institute of Medical Pathology and Mediterranean Medicine, University of Messina, Italy.
Insights
Fluvastatin, a statin, significantly reduced adhesion molecules P-selectin and ICAM-1 in hypercholesterolemia patients. This lipid-lowering therapy also improved nitric oxide generation, suggesting a biochemical basis for its cardiovascular benefits.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase inhibitors (statins) are crucial for reducing atherosclerosis-related cardiovascular events.
- Adhesion molecules like P-selectin and ICAM-1 are implicated in atherosclerosis pathogenesis.
- The impact of fluvastatin on these adhesion molecules was investigated.
Purpose of the Study:
- To evaluate the effect of fluvastatin on plasma levels of P-selectin and ICAM-1 in patients with type IIa hypercholesterolemia.
- To explore the relationship between fluvastatin treatment, adhesion molecules, and markers of endothelial function.
Main Methods:
- A double-blind, randomized study involving 26 patients with type IIa hypercholesterolemia.
- Patients received either fluvastatin (80 mg/d) or a placebo for 12 weeks.
- Plasma levels of P-selectin and ICAM-1 were measured using enzyme immunoassay.
Main Results:
- Fluvastatin significantly reduced P-selectin levels by 31% (P=0.0015) and ICAM-1 levels by 13.7% (P=0.0033).
- Fluvastatin also decreased urinary 11-dehydro-TXB2 and von Willebrand Factor levels.
- Increased nitric oxide (NO) generation was observed, with an inverse correlation between NO levels and P-selectin, 11-dehydro-TXB2, and LDL.
Conclusions:
- Fluvastatin effectively lowers key adhesion molecules involved in atherosclerosis.
- The observed increase in nitric oxide generation may contribute to the beneficial effects of statins.
- These findings provide a biochemical rationale for the clinical efficacy of HMG-CoA reductase inhibitors in managing hypercholesterolemia.
Background:
Lipid-lowering therapy with 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase inhibitors reduces the incidence of atherosclerosis-related cardiovascular events. Adhesion molecules, regulating interactions between vascular and circulating cells, may play a central role in the pathogenesis of atherosclerosis and related complications. In the present report we examined the impact of the HMG-CoA reductase inhibitor fluvastatin on plasma levels of P-selectin and ICAM-1.
Methods:
Plasma levels of P-selectin and ICAM-1 were determined using an enzyme immunoassay in 26 patients with type IIa hypercholesterolemia randomized to treatment with either fluvastatin (80 mg/d) or placebo in a double blind fashion for 12 weeks.
Results:
Fluvastatin administration reduced either P-selectin (118 +/- 63 vs 81 +/- 36 ng/mL [-31%], P = 0.0015) or ICAM-1 (264 +/- 75 vs 228 +/- 68 ng/mL [-13.7%], P = 0.0033) levels. Fluvastatin also lowered urinary 11-dehydro-TXB2 (1396 +/- 536 vs 1009 +/- 378 pg/mg creatinine [-27%], P = 0.0015) and von Willebrand Factor levels (1456 +/- 716 vs 1203 +/- 527 U/L [-17.4%], P = 0.0275), and a direct correlation was observed between P-selectin and 11-dehydro-TXB2 levels (r = 0.588, P = 0.0033). Patients treated with fluvastatin displayed an increase in nitric oxide (NO) generation, evaluated with measurements of serum NO2-/NO3-, (4.7 +/- 1 vs 8.9 +/- 3.1) mumol/L [98%], P = 0.0046). Moreover, an inverse correlation was observed between NO2-/NO3- and P-selectin (r = -0.420; P = 0.0343), 11-dehydro-TXB2 (r = -0.511; P = 0.0106), or LDL (r = -0.742; P = 0.0002) levels.
Conclusions:
These results may provide novel biochemical basis for the beneficial clinical effects of HMG-CoA reductase inhibitors in hypercholesterolemia.